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During time, both professionals and general public became aware of  the importance of  
animal welfare. This term not only covers endangered wild animal species, animals used 
in food industry, pets and experimental animals, but also animals used in production 
of  biologics. The implementation of  the 3R concept (Replacement, Reduction and 
Refi nement) is especially important in this type of  production. In this article, we describe 
for the fi rst time the low dose, low volume and multi-site immunization protocol, as 
well as appropriate ELISA we developed for production of  European anti-viper (V. 
ammodytes, long horned) antivenom in horses, which can help to signifi cantly improve 
the welfare of  the used animals. 
Key words: adjuvant, animal welfare, antivenom production, European vipers, horses, 
immunization schedule
INTRODUCTION
Though the exact number of  snake bites is unknown, an estimated 5 million people 
are bitten each year around the world, with up to 2.5 million envenomings. At least 
100 000 people die as a result of  snake bites each year and around three times as many 
amputations and other permanent disabilities are caused by snakebites annually [1].
In Europe, snake bites are relatively rare, so rare that there are no new data available. 
According to available references [2,3] in the European population (ca. 735 million), 
the annual number of  snake-bites could reach 25 000, of  which 8 000 involve 
envenomation of  which about 30 deaths could result every year. Such a low number 
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of  cases, with the death rate of  0.378%, are largely due to wide access to antivenom 
and health care services.
All venomous snakes found in Europe belong to Viperidae family. According to World 
Health Organization [4], three of  them (V. ammodytes, V. berus and V. aspis) belong 
to category 1 (“Category of  highest medical importance”), which consist of  “Highly 
venomous snakes that are common or widespread and cause numerous snakebites, 
resulting in high levels of  morbidity, disability or mortality”. Although European 
snake venoms have relatively mild potency compared to snake venoms from other 
continents [5], their bite can still cause signifi cant impacts. The best way to treat snake 
bites is by use of  antivenom, which are usually F(ab)’2 fragments or whole IgG purifi ed 
from horse antiserum.
The immunization of  horses with snake venom(s) need to be done in a way to induce 
a long-lasting and high titer antibody response against the lethal and other deleterious 
components in the immunogenic toxins. To achieve this goal, the producers typically 
immunize horses with maximum amount of  venom possible that will not induce 
the death of  the animal. A common consequence of  hyperimmunization with 
venoms achieved this way is the development of  local ulcers or abscesses (sterile and 
infected) in animals at the sites of  venom injection. One way to reduce the creation 
of  wounds is the pre-treatment of  toxins with agents that neutralize toxicity, such 
as formaldehyde. The bad side of  this approach is that it causes signifi cant loss of  
antigenic regions and induced antibodies usually fail to neutralize the native toxin [6]. 
In fact, no detoxifi cation is usually necessary if  the inoculation is made with a small 
dose of  venom well-emulsifi ed in an adjuvant such as Freund’s complete or incomplete 
adjuvants (CFA and IFA, respectively). Freund’s incomplete adjuvant contains mineral 
oil and an emulsifi er. In addition to that, CFA contains dried mycobacteria. It has 
been shown in experimental animals that CFA is one of  the most potent adjuvants 
known. However, horses are quite sensitive to CFA which tends to cause granuloma 
formation. It has been noted that the granuloma caused by CFA is due to injection 
of  a large volume (5–10 ml) of  the emulsifi ed immunogen administered at 1 or 2 
sites. Thus, the injection of  a combination of  these very damaging agents proved 
unfavorable, so some producers prefer to use other adjuvants [7,8].
Aside from Freund’s complete and incomplete adjuvants, various types of  other 
immunological adjuvants, for example aluminum salts (hydroxide and phosphate), 
bentonite and liposomes have been tested in order to enhance the effi cacy of  
immunization [9]. The choice of  adjuvant is determined by its effectiveness, side-
effects, ease of  preparation (especially on large scale) and cost.
In addition to achieving a long-lasting and high titer antibody response after 
immunogen application, today’s obligatory goal is for the immunization regimes 
used not to seriously affect the health of  the animal. All before mentioned goals 
can be achieved by increasing the number of  injection spots, adjusting the volume 
of  immunogen applied at a single site, optimal choice of  adjuvant type and optimal 
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amount of  venom used. If  the emulsifi ed immunogen is injected subcutaneously in 
small volumes (50–200 μl/site) at multiple sites of  injection, granuloma formation 
is avoided. Administered in small dose, CFA and IFA induce less tissue damage 
comparing to the damage observed after application of  high dose of  snake venom 
injected without adjuvant. The group of  Thailand colleagues published excellent 
papers about the application of  low dose, low volume, and multi-site immunization 
(hereinafter: low dose immunization) in purpose of  anti-venoms production for most 
venomous snakes of  South and Southeast Asia [10-12]. According to these papers, this 
way of  immunization leads to the highly potent monovalent and polyvalent antivenom 
production, while the administered amount of  venom does not affect the health of  
the animal. This immunization protocol was used to immunize horses with venoms of  
Elapidae (cobras and krait) and recently with Southeast Asia Viperidae venoms [13] and 
other antigens [14], as well as the immunization of  people [15].
The goal of  our experiments was to establish if  low dose immunization of  horses can 
be implemented in the production of  antiserum directed against the venom of  horned 
viper, Vipera ammodytes. We immunized the horses with V. ammodytes venom according 
to the before mentioned immunization plan and compared the observed effi cacy 
with the one accomplished after a typical high dose venom immunization [21,22]. We 
showed that the new immunization protocol induces higher yields of  antiserum, which 
results in the reduction of  the number of  horses needed for production and the cost 
of  their maintenance. In addition, the low dose immunization schedule signifi cantly 
reduced the amount of  venom and number of  snakes needed for production, risk for 
employees and thus reduced the costs of  purchase, keeping and milking of  snakes. This 
immunization protocol was shown to be more humane for horses because it did not 
induce swelling and wounds at the sites of  administration, which in turn signifi cantly 
reduced, and in some cases even completely eliminated the pain and suffering of  the 
animals. We concluded that the described protocol of  immunization of  horses with 
horned viper venom is very suitable for antivenom production and at the same time 
helps to drastically improve the welfare of  animals used in production.
The antivenom production process requires the potency test which has been accepted 
worldwide as standard bench mark [7,16] and includes the use of  mice (Mus musculus). 
There are reports [17] that around 400 mice are needed per antivenom batch in 
order to successfully complete the potency test. In addition, about 50% of  mice are 
not protected against the venom and suffer extreme pain and stress during testing. 
Moreover, traditionally employed animal assays used in this process are laborious, 
expensive and time consuming. Therefore, considering the economical and ethical 
aspects, we developed ELISA for detection of  IgG specifi c for the viper venom. Since 
we used the same venom used for immunization of  horses as antigen in our ELISA, the 
test we developed is suitable for following the development of  the immune response 
in immunized horses. We showed that in this phase of  production, the antivenom 
ELISA we developed can replace the potency test. That way, the number of  used mice 
is reduced only to the number needed for fi nal batch control.
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In this paper, we show for the fi rst time that the low dose immunization protocol 
can successfully be used for the immunization of  horses with venom of  the most 
dangerous species of  European viper. The new immunization protocol and ELISA 
method we developed and we describe in this paper refi ne, reduce and replace [18] the 
experimental/production animals and represent the practical example of  the use of  
the 3R concept in welfare of  production animals. 
MATERIAL AND METHODS
Animals
This study was conducted in accordance with the provisions of  revised Appendix 
A of  the European Convention ETS 123, and approved by the Animal Institutional 
Care and Use Committee at the Institute of  Virology, Vaccines and Sera “Torlak” 
in Belgrade, (016/2011, approved on 20th of  February 2011) and by the Veterinary 
Directorate of  Ministry of  Agriculture (011-00-00510/2011-05/11), as stated by the 
Serbian Animal Welfare Law (“Sluzbeni Glasnik RS”, no. 41/09, 39/10). 
Horses
For immunization process, we used four healthy crossbreed horses (mares), ages 5 - 
10 years old and weighing >600 kg. Animals were kept in a stable, housed in separate 
boxes. All horses were checked for the presence of  bacterial and viral diseases e.g. 
equine infectious anemia (EIA). The regular tetanus vaccination was carried out 
alongside routine clinical chemistry and hematology, and the horses were treated 
with preventive anti-parasitic treatment on regular basis. The animals were primarily 
grass fed, but in addition, alfalfa hay and oats with addition of  vitamin and mineral 
supplements and livestock salt were used. Water was available ad libitum. These horses 
have never before been used for immunization. Prior to the experiment, the horses 
were kept under quarantine.
Snakes
The venom was obtained by milking V. ammodytes adult snakes from the geographical 
area of  Serbia and Montenegro. On arrival, the snakes were examined by a specialized 
veterinarian and kept in quarantine for two months, in a purpose-built serpentarium at 
the Institute of  Virology, Vaccines and Sera “Torlak”. They were housed individually 
in separate cages with controlled temperature and humidity. Snakes were fed with 
live mice once per month and after being milked. The venom was collected at 30 
day intervals, according to a standard procedure by applying mechanical pressure to 
the venom gland by hand, i.e. active milking into Parafi lm-covered 50 ml Eppendorf  
tubes. The venom was frozen to -20 °C, before being freeze-dried and stored away 
from light at -20 °C.
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Mice
For potency test, we used outbred Intor:Swiss albino mice of  both sexes [19]. Animals 
were kept in the vivarium, housed in polycarbonate cages, fi ve mice per cage, at a 
constant room temperature of  22±1 °C with a 12-h light/dark cycle (light on from 
7:00 AM till 7:00 PM). Food and water were available ad libitum.
All animals were followed up on a daily basis and head veterinarians were contacted 
in the case of  complications. The animals were euthanized if  they presented severe 
pain or suffering, such as food and water intake diffi culties (weight loss > 25%), 
inappetence, abnormal posture or locomotion, weakness, respiratory disorders, 
vocalization disorders, or severe CNS signs during the follow up period.
Preparation of venom immunogen in CFA, IFA and aluminum salts
Horses were immunized with lyophilized V. ammodytes pulled venom VA-7. The 
lyophilization of  the venom was performed at the Institute of  Virology, Vaccines and 
Sera “Torlak”, Belgrade, Serbia. Before immunization, the venom was reconstituted 
in saline to a concentration of  2 mg/ml of  proteins. The total protein concentration 
in the venom sample was evaluated using nitrogen determination. The reconstituted 
venom was mixed with CFA, IFA or aluminum phosphate (AlPO4), depending of  
immunization scheme.
The mixture of  venom and CFA (or IFA) adjuvant was made by mixing equal parts of  
venom solution and CFA (or IFA) using two interconnected Luer lock glass syringes 
at 4 ºC. The fi nal venom concentration in the resulting emulsion was 1 mg/ml. When 
the immunogen was prepared in AlPO4, a sterile venom solution and a suspension of  
aluminum salt were mixed to fi nal venom concentration of  1 mg/ml and fi nal AlPO4 
concentration of  1%.
All chemicals and adjuvants were purchased from Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany unless otherwise indicated.
Horse immunization and bleeding schedule
Immunization of  four horses was performed as follows. The primary immunization 
was made with venom mixed with CFA as described. The initial dose of  venom was as 
low as 2 mg/horse with a total combined volume of  injection of  about 2 ml. About 
10 injections in total, 0.2 ml each were made on both sides of  the neck of  each horse. 
The immunogen was fi lled in a 5-ml plastic syringe with an 18G needle for the fi rst 
dose, and with 20 or 21G needle for second and every other application. The route of  
injection was subcutaneous. Immunization using CFA was made only once, because 
repeated use of  this adjuvant may in most cases cause serious reactions which can 
affect the health of  the animals. After 2 weeks, the horses received a booster injection 
(secondary immunization) with the same venom emulsifi ed in IFA. Volume and area 
of  the booster injection was the same as described above. Subsequent three booster 
immunizations at 2-week intervals were made with same doses of  venom mixed with 
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AlPO4 (Figure 1), until the end of  the seventh month. Buster immunizations were 
repeated until the end of  the seventh month. 
Blood (10–20 ml) was collected by venous puncture after each cycle of  immunization 
for the purpose of  potency determination. If  the potency assay confi rmed that 
the horses reached the production potency level (neutralizing potency ≥20 AU/
ml), they were bled in aseptic conditions using a sterile bottle with 9% potassium 
oxalate monohydrate solution in normal saline. Considering that all used horses for 
immunization weighed >600 kg, 8 l of  blood was collected from each animal. The 
volume ratio of  anticoagulant to blood was 1:9. The horses were then allowed to rest 
for about two weeks, depending on their physical condition. After the rest period, a 
new round of  immunization was made as described above, by injecting 3 doses of  
venom mixed with AlPO4 adjuvant, at one week intervals. In case the potency assay 
revealed that the potency did not reach the desired level (neutralizing potency <20 
AU/ml), the horses were not bled and the immunization was repeated per previous 
schedule, starting from injection of  venom in IFA adjuvant.
Potency test
The potency test was performed on outbred mice Intor:Swiss per European quality 
standards [16] Briefl y, the LD50 dose (amount of  venom suffi cient to induce death in 
50% of  animals) was determined. After that, the mice were i.v. injected with a mixture 
of  serial dilutions of  immunized horse plasma mixed with LD50 dose of  venom. The 
potency of  the plasma (material for the production of  antivenoms) or antivenom 
(the fi nal product, must be controlled) is defi ned in terms of  the number of  LD50 of  
venom that is neutralized and it is expressed in antitoxic units (AU) per ml.
Western Blot (WB) Analysis
V. ammodytes venom was resolved by SDS–PAGE with homogenous 12% 
polyacrylamide gel and electrophoretically transferred to nitrocellulose membrane 
(NC 45, Milipore Corporation Serva Electrophoresis GmbH, Heidelberg, Germany). 
To prevent non-specifi c binding, membranes were incubated with blocking buffer 3% 
skim milk ⁄ PBS for 2 hr. Horse plasma obtained after immunization was diluted in 
        Figure 1. Algorithm of  the protocol low dose, low volume, multi-site immunization.
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1% bovine serum albumin/PBS. Saturated membranes were incubated with prepared 
dilutions for 1 h at room temperature. The membranes were incubated with anti-horse 
IgG-B followed by streptavidin–phosphatase. The antibody binding was visualized by 
exposure to 5-bromo-4-chloro- 3-indolyl phosphate/nitro blue tetrazolium (BCIP/
NBT) (Sigma-Aldrich, Germany).
Anti-venom IgG ELISA
The detection of  venom specifi c horse IgG by ELISA was as follows. Vipera ammodytes 
venom pool used for coating ELISA plates were milked and lyophilized at the Institute 
of  Virology, Vaccines and Sera – Torlak, Belgrade. Nunc MaxiSorpTM ELISA 
plates (Nunc, Roskilde, Denmark) were coated (50 ml/well) with venom (2mg/
ml in PBS) by overnight adsorption (4°C) in a moist chamber. Blocking (200 ml/
well of  1% w/v BSA/PBS 2h at room temperature) and all subsequent steps in the 
ELISA were followed by washing with 0.1% Tween 20 in PBS (four times, 200 ml/
well). Appropriately diluted in 1% BSA/0.1% Tween/PBS sera or plasma samples 
(depending on the need) were incubated 1 hour at room temperature (50 ml/well). 
Each sample was assayed in duplicate. Ag-specifi c sera IgG binding was detected by 
peroxidase-conjugated anti-horse IgG (whole molecule) or by biotin-conjugated anti-
horse IgG (whole molecule), followed by incubation with ExtrAvidin-peroxidase (50 
ml/well, 1 h at room temperature). All reagents were used in accordance with the 
manufacturers` instructions. O-phenylenediamine/H2O2 (OPD) system was used 
to visualize Ag-Ab interactions. Absorbance was monitored at 492 nm and 629 nm 
(A492/620).
Anti-venom IgG ELISA Validation 
The objective of  validation of  an analytical procedure is to demonstrate that it is suitable 
for its intended purpose. Typical validation characteristics that should be considered 
are specifi city, accuracy, linearity, range, precision, and sensitivity. The validation 
of  our ELISA was performed according to the guidelines of  European Medicines 
Agency [20] and done by determination of  the above-mentioned characteristics. The 
values of  all parameters showed that our method is characterized by very high quality. 
Our ELISA enables quick and easy application in monitoring the immune response in 
horses after immunization with the venom.
ELISA for High-Affi nity Anti-venom IgG Antibodies
Before performing this ELISA, we defi ned the plasma dilutions that will be used in the 
test. For this purpose, we generated binding curves using serial dilutions of  different 
plasma prepared in 1% BSA/0.1% Tween 20/PBS and then selected the ones with the 
same absorbance at the beginning of  the linear portion of  the curve. Since different 
plasma contained different amount of  antibodies, using dilutions selected this way 
enabled for comparison of  antibody affi nities in them.
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The ELISA for high-affi nity anti-venom IgG antibodies was performed as described 
previously [21]. The procedure was similar to that given for anti-venom-specifi c ELISA 
with the difference of  one additional step. After incubation with horse plasma and 
subsequent washing with 0.1% Tween 20 ⁄ PBS, microtiter plate was incubated with 
potassium thiocyanate (KSCN/PBS) (50 l⁄well) for 30 min at room temperature. We 
used KSCN solutions in increasing concentrations (0–8 M) to detach the low affi nity 
anti-venom Abs. The plates were then washed and subsequent steps were the same as 
described in the previous section.
The relative affi nity of  anti-venom Ab binding was defi ned as the molarity of  KSCN 
that leads to dissociation of  50% of  bound Abs, i.e. the decrease of  50% in absorbance 
in comparison to the one observed for wells incubated with PBS (0 M KSCN).
Determination of the correlation coeffi cient between
the potency assay and ELISA
We examined the correlation of  the potency test and ELISA using OriginPro 8 
software.
RESULTS
The quantity of venom used for immunization of horses 
During immunization of  horses using low dose immunization protocol, 22 mg of  
venom per horse were suffi cient to achieve the production potency level of  the 
antivenom in case of  good responders, while for the maintenance or increase of  the 
achieved potency, additional 32 mg of  antivenom per horse were needed. This is at 
least 100 times less amounts of  venom used in comparison to earlier immunization 
protocols, which is already a signifi cant improvement. Previous immunization 
protocols were based on the use of  quite large doses [22] of  raw venom [23].
Potencies of antivenom produced with low dose, low volume,
multi-site immunization
The production level of  antivenom potency (>20 AU/mL) using low dose protocol 
was achieved after 100 days and it continued to rise in all immunized horses after the 
next four months, and even longer than two years in good responders (Figure 2). The 
level of  neutralizing potency was, with minor fl uctuations, maintained according to 
suggested scheme during the entire time of  the experiment. The maximum potency 
observed in good responders was up to 56 AU/mL, six months after beginning of  
immunization. In addition, this was the highest potency value achieved after any type 
of  immunization protocol.
The percentage of  good responders observed after immunization using this protocol 
is hard to discuss because we immunized only four horses, which does not represent 
a statistically relevant sample. Out of  four horses used, two achieved the desirable 
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antivenom potency after the fi rst immunization cycle and they were identifi ed as good 
responders. The other two horses needed an additional immunization cycle to achieve 
this potency level. The immune response dynamics induced by low dose immunization 
protocol is presented in Figure 2.
Horse health
There is a growing concern about the pain and suffering caused to experimental 
animals and this point has been taken seriously during our study. The horse health 
(weight, body temperature) and the reactions at the sites of  injection were closely 
monitored during the course of  the experiment. The body temperature was measured 
every day during immunization. An increase in body temperature of  0.5 °C was 
observed only the fi rst day after immunization, but not after each dose. We concluded 
that this immunization protocol does not induce a febrile state in the experimental 
animals and that it did not require any treatment. No changes in weight were observed 
in any of  the horses used in the study.
Since the horses are highly sensitive to CFA, the highest focus was directed to the neck 
area, where the application of  adjuvant was administered. Given that we used CFA in 
small doses, no granulomas were formed at injection sites in any of  the immunized 
horses and we could only observe a mild edema.
ELISA validation
The critical validation parameters are summarized in Table 1. The specifi city of  the 
method was high, and the linearity and scope had correct values. Furthermore, according 
to the literature data [24], intra- and inter-assay coeffi cient of  variation of  10 % or less 
is considered to be satisfactory. The values of  coeffi cient of  variation obtained in our 
ELISA were under 5 %, which indicates high-precision assay performance for testing 
samples once or more times. In addition, given that the value of  CV inter-lab was 
Figure 2. Immune responses (the antivenom neutralization potency) in horses against V. 
ammodytes venom induced by multisite, low dose, immunization protocol. Dashed arrows on 
the x axis represent time points of  venom application. Symbols ▲, ■, ▼ and ● represent 
each individual horse. ▼ and ● – low responders; ■ and ▲ – good responders. Dashed line 
represents antivenom potency production level (20 AU/ml).
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satisfactorily within 10–15 % [25], our ELISA is characterized by high reproducibility. 
Based on validation characteristics, we can conclude that the ELISA we developed 
is reliable and that it can be used for control horse immunization part of  antivenom 
production (Figure 3).
Table 1. The summary of  validated characteristics of  ELISA for detection of  horse IgG 
antibodies specifi c for V. ammodytes venom proteins
Validation characteristics Value
Specifi city High
Linearity 1:1 000-1:250 000 dilution of  standard plasma
Range 1:3 000-1:105 000 dilution of  standard plasma
Accuracy High
Precision
Repeatability (ref. value: ≤ 10%) 3.4%
Intermediate precision (ref. value: ≤ 10%) 3.4%
Reproducibility (ref. value: 10%-15%) 11.1%
Detection Limit 0.02
Robustness Good
We tested what results were obtained depending on whether the sample was plasma 
or serum and concluded that there is no difference in the results of  the ELIZA test. 
Correlation between potency test and ELISA
According to results of  our experiments (Figure 4), the calculated correlation 
coeffi cient between potency test and anti-venom IgG ELISA was 0.682 (68%).
Figure 3. Development of  venom specifi c IgG antibodies induced according to low dose, 
monitored by ELISA.
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Titer and affi nity of venom-specifi c horse IgG induced by old
and new protocol immunization
On Figure 5 it is easy to notice that immunization using the new protocol leads to 
signifi cant increase in anti-venom IgG antibody as measured by ELISA. Comparing 
to the previous protocol, the measured titers were even eight dilution factors higher: 
for the classic protocol, the titer was 512 x 103, and for the new one it was 4 096 x 103.
According to that, for affi nity determination we used dilution of  1:8 and 1:64 for 
old and new immunization protocols [21,22], respectively. We determined that 7.5 M 
KSCN was needed to detach 50% of  bound anti-venom IgG antibodies from plasma 
of  both immunization protocols.
This result was confi rmed by Western blotting (Figure 6), where membrane staining 
is much more intense with plasma obtained according to the low-dose protocol. To 
achieve a similar WB image with both protocols plasma, the one obtained according 
to the new protocol needed to be diluted at least four times. At the same time, WB 
confi rms the specifi city of  the induced antibodies for non-reduced venom proteins. 
No binding in reduced conditions was detected (not shown).
Figure 4. Correlation between ELISA antibody levels (absorbance at 492/620 nm) and in 
vivo neutralizing potency of  V. ammodytes antivenoms. Microwell plates were coated with the 
V. ammodytes venom. Horse antivenom plasma was used at 1:32 000 dilution. All data points 
represent means of  three experiments.
Figure 5. Titer of  venom-specifi c horse IgG induced by the old and the low dose immunization 
protocol. ■-low dose, ●-old protocol. The fi gure shows mean values of  four horse titers 
immunized according to the low dose protocol and the mean values of  eight horse titers 
immunized according to the old protocol.
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DISCUSSION
Improving antiviperinum production by immunizing horses with horned viper toxin 
is still important because horned viper is the most venomous and most widespread 
European venomous snake. In addition, V. ammodytes antivenom is cross-reactive with 
the venom of  the common European adder (V. berus), as well as with venoms of  other 
European Viperidae [26,27]. In this paper, we describe a new immunization protocol 
used for anti-viper antivenom production. The horses were immunized according to 
low dose, low volume, multi-site protocol [10,11] which was recommended by the 
WHO [7,8]. Using this protocol, results both in increase in productivity of  antivenom 
production and in drastic reduction of  animals (horses, snakes and mice) used in the 
process. It is also very useful when a limited amount of  antigen is available.
The immunization schedule must lead to the highest titer of  antibodies with the 
lowest antigen consumption. We considered the immunization protocol successful if  
the achieved antivenom potency is ≥20 AU/mL six months after immunization start, 
and if  it remained at the same level or higher in the next six months. In our case, this 
potency level was achieved much earlier than 6 months after the immunization protocol 
was initiated, specifi cally in 14 weeks. In two immunized horses, the desired titer ≥20 
AU/mL was achieved after the fi rst immunization cycle, while in the remaining two 
horses, additional cycle was needed to hit this mark.
Figure 6. Ponceau S staining and Western blotting of  V. ammodytes venom protein profi le 
on 12% PAGE in non-reducing conditions. A and B – Ponceau S stained membrane; A - V. 
ammodytes venom, B - protein marker SM 0661 (Fermentas); C-F WB; C – normal horse plasma; 
D - horse plasma old protocol, E and F –horse plasma low dose protocol, diluted 10 000 and 
40 000 times, respectively.
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In the end, we established that after reaching the production level, the neutralizing 
potency could be maintained for at least two years.
In addition to fast manufacture, the quality of  antivenom, i.e. antiserum of  high 
antitoxin potency is of  utmost importance in the antivenom production process. In 
classic antivenom production, the antivenom quality was achieved by slow increase 
in the amount of  applied venom. The application of  high venom doses used at the 
end of  immunization schedule not only causes the local tissue damage in immunized 
animals, but also is not immunologically justifi ed because a too high concentration 
of  immunogen can overwhelm the immune system and cause clonal anergy. The 
induction of  high potency anti-viper antivenom by low dose of  antigen using the 
new protocol was achieved by addition of  adjuvants to the immunization mixture 
[28]. The most important result of  this approach was the induction of  high titer anti-
viperin venom (measured by potency test), which allows for high yields of  produced 
antiserum even with smaller amounts of  animal blood used, when compared to the 
classic immunization protocol (Figure 2).
The combination of  used adjuvants (CFA, IFA and aluminum phosphate) was shown 
to be very successful. First, CFA was used because of  its high potency, because 
mycobacterial components within CFA signal T lymphocytes to assume a Th1 profi le. 
Since it was used only in one dose and in low volume, the application of  CFA did not 
affect the immunized horses. Secondly, IFA can trigger depot generation and induction 
of  MHC responses. IFA induces a predominantly Th2-biased response with some 
Th1 cellular response. And fi nally, aluminum phosphate adjuvant was used because 
of  its safety and because it has already been used in antivenom production, as well as 
in human vaccine production for over 70 years. It has been recognized that aluminum 
adjuvants are strong inducers of  antibody-mediated immune responses, but only 
poorly stimulate cell-mediated immunity. Each of  these three adjuvants promote the 
immune response using different activation mechanisms and using them together, the 
immune response is modulated in a way that results in maximum activation without 
causing side effects.
Subcutaneous route of  injection recruits a large number of  antigen presenting cells 
which consequently results in high antibody response. The immunization sites were 
in the areas close to major lymph nodes, preferably on the animals’ neck. In our 
immunization procedure, we used small volume (50–200 μL) injections at as many as 
8–12 sites to maximize the total surface area of  the immunogen droplets and in turn 
enhance the interaction with the antigen presenting cells and the immune response. 
This low amount of  venom used in such a small volume, even when administered with 
CFA and IFA, does not induce any edema, wounds or abscesses.
All of  these factors combined caused the use of  low dose immunization protocol 
to result in high antivenom yields achieved by using signifi cantly less venom when 
compared to the classic immunization protocol. A simple comparison between the 
two immunization protocols reveals an impressive 100 x – 140 x reduction of  the 
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amount of  toxin used (22 mg of  toxin used in the new protocol vs 3.16 g used in 
the classic protocol [21,22]. The preparation of  immunogens and the immunization 
protocol presented in this paper are technically simple and economical, and use a 
minimal amount of  venom, which results in a signifi cant reduction in the number of  
snakes needed, as well as in reduction of  risks and work hours and materials used for 
maintenance and milking of  the venom. This not only improves the fi nancial aspect of  
the process, but also the ethical aspect of  human and animal welfare.
The ELISA described in our paper showed that the new immunization protocol 
induces antivenom IgG antibody titers of  eight times higher dilution factor when 
compared to the ones observed after using the classical protocol (Figure 5, Figure 6). 
This result can be caused by the increase in the concentration of  produced IgG, or 
by the increase in the affi nity of  these antibodies. Since we showed that the antibody 
affi nities in both protocols were on the same level, we can conclude that the increased 
titer observed after using the new immunization protocol occurs as a result of  the 
increase in the concentration of  produced antibodies [29]. Although this is favorable 
for antivenom production, it is important to remember that the induction of  high 
antibody concentrations can lead to hyperglobulinemia. In horses, hyperglobulinemia 
can be manifested with cryoglobulinemia, which can lead to glomerulonephritis, 
swelling and skin ulcers of  the limbs in the winter [30]. Using plasmapheresis during 
the bleeding procedure and by control of  the antibody titer can successfully protect 
the horses from developing these complications.
The effi ciency of  the antivenom and quality of  plasma as a starting material for 
antivenom production is traditionally assessed in vivo by measuring the neutralizing 
potency in mice [16]. The cost and inconvenience dealing with the animals, the 
suffering and death of  a large number of  animals, and the variable irreproducible 
results obtained are among the usual problems encountered with the in vivo assays. 
Several investigators have correlated the potency of  the produced antivenoms to other 
in vitro assays, especially ELISA [31,32]. 
The correlation between the potency test and ELISA developed in our laboratory 
was 68%, which was similar to the values reported in similar studies using different 
venoms [33]. At the fi rst glance, the correlation coeffi cient of  68% might seem low 
and ELISA cannot replace the potency test in assessing the plasma quality (effi ciency). 
The observed difference in the two assays can be explained by the fact that ELISA 
detects IgG antibodies specifi c to all immunogenic proteins of  the viper venom, while 
the potency assay measures only the functional (neutralizing) capacity of  the IgG 
specifi c to toxic components of  the venom. Since the immune response develops 
independently of  the toxicity of  protein components, ELISA can be used to follow 
the increase in IgG antibody concentrations and to detect the point when the immune 
response achieves the plateau, after which the potency assay can be used to make 
necessary decisions during antivenom production. An aliquot of  suitable plasma with 
a known neutralizing potency value can be used as a standard in ELISA and in that way 
the achieved potency level can be detected even before the plateau phase. Additionally, 
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ELISA is sensitive enough and can be used during the early immunization phase to 
differentiate between good and poor responders, which is hard to accomplish using 
conventional in vivo assay at that stage of  the process. This is not only fi nancially but 
also ethically signifi cant because it can help prevent the use of  low-responder horses 
for antivenom production and at the same time prevent the unnecessary immunization 
during the long period of  time. Figure 3 illustrates the course of  immunization 
determined by ELISA.
Bearing in mind that the viper venom consists of  139 protein components, of  which 
only 38 are toxic [34], it can be concluded that the observed correlation coeffi cient 
between ELISA and potency assay is actually very high. The most probable reason 
for this is the fact that the most potent neurotoxic components of  the venom, 
ammodytoxins, are at the same time the strongest immunogens [35]. Mice, which 
are used for potency assays, are actually the most susceptible to these neurotoxic 
components. This is the reason why achieving high correlation between ELISA and 
potency test is not that signifi cant.
In addition to immune response development, ELISA can be used to follow different 
stages of  the plasma fractionating process, but not in the fi nal batch of  antivenom for 
human usage which needs to be tested using classical in vivo test in mice (potency test). 
Namely, contrary to mice, people are more susceptible to hemorrhagic components 
of  the venom [36] so in vivo assays show little or no correlation with envenoming and 
therapy in humans [37]. Although the potency test does not precisely measure the 
level of  protection the produced antivenom provides to humans, currently there is 
no other, more suitable assay developed for this purpose, which makes it a golden 
standard until a better method is developed.
The recommended immunization protocol of  horses using V. ammodytes venom in 
a small dose, small volume and low concentration and its multi-site application with 
adjuvants leads to reduced venom burden in immunized horses. At the same time, it 
results in high quality and high yields of  the produced antivenom, accompanied by 
reduction in costs of  antivenom production and the time needed for its completion. 
This is also the fi rst report of  the refi ned immunization scheme being applied to 
European Viperidae antivenom production.
In the end, it is very important to stress that by the use of  the immunization protocol 
presented in this paper, we signifi cantly reduced the number of  horses, snakes and mice 
needed for the process. We also successfully replaced the potency test, which requires 
the use of  mice, with ELISA for the most part during the course of  immunization. 
And fi nally, we signifi cantly refi ned the procedures used on horses. Altogether, our 
paper represents a good example of  successful implementation of  the 3R principle in 
production of  biologics.
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PRIMENA 3R KONCEPTA U PRODUKCIJI EVROPSKOG 
ANTIVENOMA NA KONJIMA – IMUNIZACIONI PROTOKOL
SA MALIM VOLUMENOM NA VIŠE MESTA I ELISA
MILOVANOVIĆ Vladimir, DIMITRIJEVIĆ Ljiljana, PETRUŠIĆ Vladimir, 
KADRIĆ Jasminka, MINIĆ Rajna, ŽIVKOVIĆ Irena
Tokom vremena, stručna i opšta javnost postala je svesna važnosti dobrobiti životinja. 
Ovaj pojam se ne odnosi samo na divlje životinjske vrste, životinje koje se koriste u 
prehrambenoj industriji, kućne ljubimce i eksperimentalne životinje, već i na životinje 
koje se koriste u proizvodnji bioloških preparata. Naročito je važno implementirati 3R 
koncept (Replacement - zamena, Reduction - smanjenje and Refi nement - poboljšanje) 
u ovaj tip proizvodnje. Ovde prvi put opisujemo primenu novog imunizacionog pro-
tokola za konje, malom dozom V. Ammodytes venoma, aplikovanog u maloj zapremini 
i na mnogo mesta, tokom produkcije antivenoma za ujede evropskih vipera. Proto-
kol imunizacije, zajedno sa razvijenom ELISA metodom sa istim antigenom, može 
značajno da poboljša dobrobit životinja koje se koriste u proizvodnji evropskog anti-
viperinuma.
